These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 32777859)

  • 1. What is required for achieving hepatitis C virus elimination in Singapore? A modeling study.
    Chaillon A; Thurairajah PH; Hsiang JC; Martin NK
    J Gastroenterol Hepatol; 2021 Apr; 36(4):1110-1117. PubMed ID: 32777859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modelling the elimination of hepatitis C as a public health threat in Iceland: A goal attainable by 2020.
    Scott N; Ólafsson S; Gottfreðsson M; Tyrfingsson T; Rúnarsdóttir V; Hansdottir I; Hernandez UB; Sigmundsdóttir G; Hellard M
    J Hepatol; 2018 May; 68(5):932-939. PubMed ID: 29274408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is hepatitis C virus (HCV) elimination achievable among people who inject drugs in Tijuana, Mexico? A modeling analysis.
    Marquez LK; Cepeda JA; Bórquez A; Strathdee SA; Gonzalez-Zúñiga PE; Fleiz C; Rafful C; Garfein RS; Kiene SM; Brodine S; Martin NK
    Int J Drug Policy; 2021 Feb; 88():102710. PubMed ID: 32165050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment scale-up to achieve global HCV incidence and mortality elimination targets: a cost-effectiveness model.
    Scott N; McBryde ES; Thompson A; Doyle JS; Hellard ME
    Gut; 2017 Aug; 66(8):1507-1515. PubMed ID: 27196586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modelling the impact of a national scale-up of interventions on hepatitis C virus transmission among people who inject drugs in Scotland.
    Fraser H; Mukandavire C; Martin NK; Goldberg D; Palmateer N; Munro A; Taylor A; Hickman M; Hutchinson S; Vickerman P
    Addiction; 2018 Nov; 113(11):2118-2131. PubMed ID: 29781207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mathematical modeling of hepatitis c virus (HCV) prevention among people who inject drugs: A review of the literature and insights for elimination strategies.
    Pitcher AB; Borquez A; Skaathun B; Martin NK
    J Theor Biol; 2019 Nov; 481():194-201. PubMed ID: 30452959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy.
    Martin NK; Hickman M; Hutchinson SJ; Goldberg DJ; Vickerman P
    Clin Infect Dis; 2013 Aug; 57 Suppl 2(Suppl 2):S39-45. PubMed ID: 23884064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is hepatitis C virus elimination possible among people living with HIV and what will it take to achieve it?
    Martin NK; Boerekamps A; Hill AM; Rijnders BJA
    J Int AIDS Soc; 2018 Apr; 21 Suppl 2(Suppl Suppl 2):e25062. PubMed ID: 29633560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elimination of HCV as a public health concern among people who inject drugs by 2030 - What will it take to get there?
    Grebely J; Dore GJ; Morin S; Rockstroh JK; Klein MB
    J Int AIDS Soc; 2017 Jul; 20(1):22146. PubMed ID: 28782335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Scaling-up HCV prevention and treatment interventions in rural United States-model projections for tackling an increasing epidemic.
    Fraser H; Zibbell J; Hoerger T; Hariri S; Vellozzi C; Martin NK; Kral AH; Hickman M; Ward JW; Vickerman P
    Addiction; 2018 Jan; 113(1):173-182. PubMed ID: 28734093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Public health interventions, priority populations, and the impact of COVID-19 disruptions on hepatitis C elimination among people who have injected drugs in Montreal (Canada): A modeling study.
    Lanièce Delaunay C; Klein MB; Godin A; Cox J; Kronfli N; Lebouché B; Doyle C; Maheu-Giroux M
    Int J Drug Policy; 2023 Jun; 116():104026. PubMed ID: 37075626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modeling Hepatitis C Elimination Among People Who Inject Drugs in New Hampshire.
    Blake A; Smith JE
    JAMA Netw Open; 2021 Aug; 4(8):e2119092. PubMed ID: 34342652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of hepatitis C virus (HCV) elimination strategies among people who inject drugs (PWID) in Tijuana, Mexico.
    Marquez LK; Fleiz C; Burgos JL; Cepeda JA; McIntosh C; Garfein RS; Kiene SM; Brodine S; Strathdee SA; Martin NK
    Addiction; 2021 Oct; 116(10):2734-2745. PubMed ID: 33620750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modeling the role of incarceration in HCV transmission and prevention amongst people who inject drugs in rural Kentucky.
    Stone J; Fraser H; Young AM; Havens JR; Vickerman P
    Int J Drug Policy; 2021 Feb; 88():102707. PubMed ID: 32151496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model.
    Heffernan A; Cooke GS; Nayagam S; Thursz M; Hallett TB
    Lancet; 2019 Mar; 393(10178):1319-1329. PubMed ID: 30704789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid decline in HCV incidence among people who inject drugs associated with national scale-up in coverage of a combination of harm reduction interventions.
    Palmateer NE; Taylor A; Goldberg DJ; Munro A; Aitken C; Shepherd SJ; McAllister G; Gunson R; Hutchinson SJ
    PLoS One; 2014; 9(8):e104515. PubMed ID: 25110927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe.
    Fraser H; Martin NK; Brummer-Korvenkontio H; Carrieri P; Dalgard O; Dillon J; Goldberg D; Hutchinson S; Jauffret-Roustide M; Kåberg M; Matser AA; Matičič M; Midgard H; Mravcik V; Øvrehus A; Prins M; Reimer J; Robaeys G; Schulte B; van Santen DK; Zimmermann R; Vickerman P; Hickman M
    J Hepatol; 2018 Mar; 68(3):402-411. PubMed ID: 29080808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment and primary prevention in people who inject drugs for chronic hepatitis C infection: is elimination possible in a high-prevalence setting?
    Gountas I; Sypsa V; Anagnostou O; Martin N; Vickerman P; Kafetzopoulos E; Hatzakis A
    Addiction; 2017 Jul; 112(7):1290-1299. PubMed ID: 28107585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade.
    Scott N; Doyle JS; Wilson DP; Wade A; Howell J; Pedrana A; Thompson A; Hellard ME
    Int J Drug Policy; 2017 Sep; 47():107-116. PubMed ID: 28797497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modeling the Impacts of Prevention and Treatment Interventions on Hepatitis C Among People Who Inject Drugs in China.
    Fang K; Wang HL; Lin Y; Li S; Wu J
    Infect Dis Ther; 2023 Apr; 12(4):1043-1055. PubMed ID: 36894824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.